Skip to main content

Advertisement

Table 2 miR-10b-5p: copies per microliter of serum according to clinicopathological features

From: Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR

Feature Cohort A (Italy) Cohort B (USA)
Average copies/μL ± SD Average copies/μL ± SD
(n = number of patients) (n = number of patients)
Tumor size (pT) pT1 108.7 ± 78.0 (n = 19) 98.6 ± 47.3 (n = 28)
pT2 97.3 ± 55.9 (n = 6) 143.4 ± 70.3 (n = 27)
pT3 / 75.0 ± 11.9 (n = 4)
Lymph node involvement (pN) pN0 88.7 ± 37.2 (n = 18) 101.2 ± 54.6 (n = 35)
pN1-2-3 113.3 ± 89.4 (n = 7) 145.2 ± 70.8 (n = 23)
Stage I 82.9 ± 28.5 (n = 14) 91.3 ± 45.9 (n = 23)
II 107.7 ± 79.9 (n = 10) 128.0 ± 61.8 (n = 25)
III 134.0 (n = 1) 130.5 ± 60.2 (n = 8)
IV / 242.2 ± 110.3 (n = 2)
Grade I 80.8 ± 36.5 (n = 5) 114.9 ± 43.2 (n = 11)
II 112.7 ± 88.6 (n = 18) 91.2 ± 58.8 (n = 13)
III 105.0 ± 54.3 (n = 5) 136.0 ± 74.81 (n = 34)
ER/PR status ER+/PR+ 142.1 ± 98.44 (n = 17) 115.0 ± 60.1 (n = 35)
ER-/PR- 74.0 (n = 1) 131.9 ± 89.4 (n = 16)
HER2/neu receptor Positive 103.7 ± 80.8 (n = 3) 112.9 ± 65.5 (n = 11)
Negative 115.8 ± 88.4 (n = 25) 145.8 ± 75.0 (n = 44)
Triple Negatives ER-/PR-/HER2- 74.0 (n = 1) 117.8 ± 90.2 (n = 9)
Others 118.2 ± 85.61 (n = 27) 121.5 ± 63.36 (n = 49)
  1. ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growth factor receptor 2